H1OL34 Stock Overview
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$366.30 |
| 52 Week High | US$366.30 |
| 52 Week Low | US$337.29 |
| Beta | 1.02 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 3.04% |
| 5 Year Change | n/a |
| Change since IPO | 61.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| H1OL34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 0.8% |
| 1Y | n/a | -2.5% | 15.0% |
Return vs Industry: Insufficient data to determine how H1OL34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how H1OL34 performed against the BR Market.
Price Volatility
| H1OL34 volatility | |
|---|---|
| H1OL34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: H1OL34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine H1OL34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 6,990 | Steve MacMillan | www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| H1OL34 fundamental statistics | |
|---|---|
| Market cap | R$91.24b |
| Earnings (TTM) | R$2.64b |
| Revenue (TTM) | R$20.31b |
34.6x
P/E Ratio4.5x
P/S RatioIs H1OL34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H1OL34 income statement (TTM) | |
|---|---|
| Revenue | US$3.97b |
| Cost of Revenue | US$1.55b |
| Gross Profit | US$2.42b |
| Other Expenses | US$1.91b |
| Earnings | US$515.10m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 2.19 |
| Gross Margin | 60.99% |
| Net Profit Margin | 12.98% |
| Debt/Equity Ratio | 55.0% |
How did H1OL34 perform over the long term?
See historical performance and comparison